Ana S. Garcia Moreno

Ana S. Garcia Moreno

Auto-generated profile, based on publicly available information

Ana S. Garcia Moreno

Division of Thoracic Surgery, Department of Surgery, Mayo Clinic, Rochester, Minnesota

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2024 in Hepatology Communications
Verified
Journal Article
Open access
AMAna S. Garcia Moreno
Ana S. Garcia Moreno
MGMaria E. Guicciardi
Maria E. Guicciardi
AWAlexander Q. Wixom
Alexander Q. Wixom
EJErik Jessen
Erik Jessen
JYJingchun Yang
Jingchun Yang
GGGregory J. Gores
Gregory J. Gores
Background: The pathogenesis of primary sclerosing cholangitis (PSC) is unclear, although studies implicate IL-17A as an inflammatory mediator in this disease. However, a direct assessment of IL-17 signaling in PSC cholangiocytes is lacking. In this study, we aimed to investigate and characterize the response of PSC extrahepatic cholangiocyte organoids (ECO) to IL-17A stimulation. Methods: Cholangiocytes obtained from patients with PSC and without PSC by endoscopic retrograde cholangiography were cultured as ECO. The ECO were treated with vehicle or IL-17A and assessed by transcriptomics, secretome analysis, and genome sequencing. Results: Unsupervised clustering of all integrated single-cell RNA sequencing data identified 8 cholangiocyte clusters that did not differ between PSC and non-PSC ECO. However, PSC ECO cells demonstrated a robust response to IL-17 treatment, as noted by an increased number of differentially expressed genes by transcriptomics and more abundant chemokine and cytokine expression and secretion. After rigorous filtering, genome sequencing identified candidate somatic variants shared among PSC ECO from unrelated individuals. However, no candidate rare variants in genes regulating the IL-17 pathway were identified, but rare variants regulating the MAPK signaling pathway were present in all PSC ECO. Conclusions: PSC and non-PSC patient-derived ECO respond differently to IL-17 stimulation, implicating this pathway in the pathogenesis of PSC.

23 March 2025 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
RRRafaela V.P. Ribeiro
Rafaela V.P. Ribeiro
SASalah E. Altarabsheh
Salah E. Altarabsheh
DSDaemiel L. Segamanasinghe
Daemiel L. Segamanasinghe
ILIsmar W. Lopez-Muralles
Ismar W. Lopez-Muralles
AMAna S. Garcia Moreno
Ana S. Garcia Moreno
SSSahar A. Saddoughi
Sahar A. Saddoughi